GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...
Dyne Therapeutics has initiated the Phase III HARMONIA trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (z-basivarsen, also called DYNE-101) in individuals diagnosed ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果